Appendix B to Part B—[Revised]

Appendix B to Part 946 is revised to read as follows:

APPENDIX B TO PART 946—AIRPORT TABLES

"A" Level Service Airports:	
*Akron, OH	CAK
*Albany, NY	ALB
*Atlanta, GA	ATL
*Baltimore, MD	BWI
*Boston, MA	BOS
Charlotte, NC	CLT
*Chicago-O'Hare (AV), IL	ORD
Cincinnati, OH	CVG
Columbus, OH	CMH
*Dayton, OH	DAY
*Des Moines, IA	DSM
*Detroit, MI	DTW
*Fairbanks, AK	FAI
*Fresno, CA	FAT
*Greensboro, NC	GSO
*Hartford, CT	BDL
Indianapolis, IN	IND
*Kansas City, MO	MCI
*Lansing, MI	LAN
Las Vegas, NV	LAS
Los Angeles (AV), CA	LAX
*Louisville, KY	SDF
*Milwaukee, WI	MKE
*Minneapolis, MN	MSP
*Newark, NJ	EWR
*Oklahoma City, OK	OKC
Phoenix, AZ	PHX
*Portland, OR	PDX
*Providence, RI	PVD
*Raleigh, NC	RDU
*Richmoind, VA	RIC
*Rochester, NY	ROC
*Rockford, IL	RFD
*San Antonio, TX	SAT
San Diego, CA	SAN
*San Francisco, CA	SFO
*Spokane, WA	GEG
*Syracuse, NY	SYR
Tallahassee, FL	TUL
Tulsa, OK	TUL
"B" Level Service Airports:	
*Baton Rouge, LA	BTR
*Billings, MT	BIL
*Charleston, WV	CRW
*Chattanooga, TN	CHA
Colorado Springs, CO	COS
Daytona Beach, FL	DAB
El Paso, TX	ELP
Flint, MI	FNT
Fort Wayne, IN	FWA
Honolulu, HI	HNL
*Huntsville, AL	HSV
*Knoxville, TN	TYS
*Lincoln, NE	LNK
Lubbock, TX	LBB
*Madison, WI	MSN
*Moline, IL	MLI
*Montgomery, AL	MGM
*Muskegon, MI	MKG
*Norfolk, VA	ORF
Peoria, IL	PIA
*Savannah, GA	SAV
*South Bend, IN	SBN
Tucson, AZ	TUS
*West Palm Beach, FL	PBI
*Youngstown, OH	YNG
"C" Level Service Airports:	
Abilene, TX	ABI
Allentown, PA	ABE
Asheville, NC	AVL
Athens, GA	AHN
Atlantic City, NJ	ACY
Augusta, GA	AGS
Austin, TX	AUS
Bakersfield, CA	BFL
Bridgeport, CT	BDR
Bristol, TN	TRI
Casper, WY	CPR
Columbia, MO	COU
Columbus, GA	CSG
Dubuque, IA	DBQ
Elkins, WV	EKN
Erie, PA	ERI
Eugene, OR	EUG
Evansville, IN	EVV
Fargo, ND	FAR
Fort Smith, AR	FSM
Grand Island, NE	GRI
Helena, MT	HLN
Huntington, WV	HTS
Huron, SD	HON
Kahului, HI	OGG
Key West, FL	EYW
Lewiston, ID	LWS
Lexington, KY	LEX
Lynchburg, VA	LYH
Macon, GA	MCN
Mansfield, OH	MFD
Meridian, MS	MEI
Olympia, WA	OLM
Port Arthur, TX	BPT
Portland, ME	PWM
Rapid City, SD	RAP
Redding, CA	RDD
Reno, NV	RNO
Roanoke, VA	ROA
Rochester, MN	RST
Salem, OR	SLE
Santa Maria, CA	SMX
Sioux City, IA	SUX
Springfield, IL	SPI
Stockton, CA	SCK
Toledo, OH	TOL
Waco, TX	ACT
Waterloo, IA	ALO
Wilkes-Barre, PA	AVP
Williamsport, PA	IPT
Wilmington, DE	ILG
Worcester, MA	ORH
Yakima, WA	YKM
"D" Level Service Airports:	
Alamosa, CO	ALS
Alpena, MI	APN
Astoria, OR	AST
Beckley, WV	BKW
Caribou, ME	CAR
Concordia, KS	CNK
Concord, NH	CON
Ely, NV	ELY
Havre, MT	HVR
Homer, AK	HOM
Houghton Lake, MI	HTL
International Falls, MN	INL
Kalispell, MT	FCA
Lander, WY	LND
Norfolk, NE	OFK
Sault Ste. Marie, MI	SSM
Scottsbluff, NE	BFF
Sheridan, WY	SHR
St. Cloud, MN	STC
Tupelo, MS	TUP
Valentine, NE	VTN
Victoria, TX	VCT
Wichita, Falls, TX	SPS
Williston, ND	ISN
Winnemucca, NV	WMC

*Long-line RVR designated site.

[FR Doc. 97–18913 Filed 7–18–97; 8:45 am]

BILLING CODE 3510–12–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 510, 520, and 522

Animal Drugs, Feeds, and Related Products

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to remove those portions reflecting approval of one new animal drug application (NADA) held by Babineaux's Veterinary Products for diethylcarbamazine citrate syrup, and two NADA's held by Schein Pharmaceutical/Steris Laboratories for phenylbutazone injection and oxytocin injection. In a notice published elsewhere in this issue of the **Federal Register**, FDA is withdrawing approval of these NADA's as requested by their sponsors.

EFFECTIVE DATE: July 31, 1997.

FOR FURTHER INFORMATION CONTACT: Mohammad I. Sharar, Center for Veterinary Medicine (HFV–216), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1722.

SUPPLEMENTARY INFORMATION: Babineaux's Veterinary Products, Inc., 6425 Airline Hwy., Metairie, LA 70003, is the sponsor of NADA 46–147 for Dirocide (diethylcarbamazine citrate) Syrup. Schein Pharmaceutical, Inc./ Steris Laboratories, Inc., 620 North 51st Ave., Phoenix, AZ 85043–4705, is the sponsor of NADA 48–391 for phenylbutazone injection, and NADA 49–183 for oxytocin injection.

The sponsors requested withdrawal of approval of the NADA's under 21 CFR 514.115(d) because the products are no longer being marketed.

The regulations are amended in 21 CFR 520.622b(a)(2), 522.1680(b), and 522.1720(b)(2) to remove those portions which reflect approval of these NADA's.

Also, with the withdrawal of approval of NADA 46–147, Babineaux's Veterinary Products is no longer the sponsor of any approved NADA's. Therefore, 21 CFR 510.600(c)(1) and (2) are amended to remove entries for this firm.

List of Subjects

21 CFR Part 510

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

21 CFR Part 520

Animal drugs.

21 CFR Part 522

Animal drugs.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under the authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510, 520, and 522 are amended as follows:

PART 510—NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 510 continues to read as follows:

Authority: Secs. 201, 301, 501 502, 503, 512, 701, 721 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e).

§ 510.600 [Amended]

2. Section 510.600 *Names, addresses, and drug labeler codes of sponsors of approved applications* is amended in paragraph (c)(1) by removing the entry for ''Babineaux's Veterinary Products, Inc.'' and in paragraph (c)(2) by removing the entry for ''021188''.

PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

3. The authority citation for 21 CFR part 520 continues to read as follows:

Authority: Secs. 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b).

§ 520.622b [Amended]

4. Section 520.622b *Diethylcarbamazine citrate syrup* is amended in paragraph (a)(2) by removing the phrase ''Nos. 021188 and'' and adding in its place ''No.''.

PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

5. The authority citation for 21 CFR part 522 continues to read as follows:

Authority: Sec. 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b).

§ 522.1680 [Amended]

6. Section 522.1680 *Oxytocin injection* is amended in paragraph (b) by removing the number ''000402''.

§ 522.1720 [Amended]

7. Section 522.1720 *Phenylbutazone injection* is amended in paragraph (b)(2) by removing the number ''000402''.

Dated: July 17, 1997.

Stephen F. Sundlof,

Director, Center for Veterinary Medicine.

[FR Doc. 97–19066 Filed 7–18–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 520

Oral Dosage Form New Animal Drugs; Enrofloxacin Tablets

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Bayer Corp., Agriculture Division, Animal Health. The supplemental NADA provides for revised conditions for use (dose, indications, and limitations) of enrofloxacin tablets in dogs and cats for the management of diseases associated with bacteria susceptible to enrofloxacin.

EFFECTIVE DATE: July 21, 1997.

FOR FURTHER INFORMATION CONTACT: Linda M. Wilmot, Center for Veterinary Medicine (HFV–114), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–0614.

SUPPLEMENTARY INFORMATION: Bayer Corp., Agriculture Division, Animal Health, P.O. Box 390, Shawnee Mission, KS 66201, filed supplemental NADA 140–441 Baytril® Tablets (5.7, 22.7, or 68.0 milligrams (mg) enrofloxacin). The supplemental NADA provides for revised conditions for use of enrofloxacin in dogs and cats for management of diseases associated with bacteria susceptible to enrofloxacin by administering the tablets orally at a rate of 5 to 20 mg per kilogram (2.27 to 9.07 mg/pounds) of body weight as a single daily dose or divided and given in 2 equal daily doses at 12 hour intervals for at least 2 to 3 days beyond cessation of clinical signs, to a maximum of 30 days. The supplemental NADA is approved as of June 19, 1997, and the regulations are amended in § 520.812 (21 CFR 520.812) by redesignating paragraph (c) as paragraph (d) and by reserving new paragraph (c) to provide for more uniform regulations and future expansion. Newly redesignated § 520.812(d) is revised to reflect the approval. The basis for approval is discussed in the freedom of information summary.

In accordance with the freedom of information provisions of 21 CFR part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857, between 9 a.m. and 4 p.m., Monday through Friday.

The agency has carefully considered the potential environmental effects of this action. FDA has concluded that the action will not have a significant impact on the human environment, and that an environmental impact statement is not required. The agency's finding of no significant impact and the evidence supporting that finding, contained in an environmental assessment, may be seen in the Dockets Management Branch (address above) between 9 a.m. and 4 p.m., Monday through Friday.

List of Subjects in 21 CFR Part 520

Animal drugs.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is amended as follows:

PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 520 continues to read as follows:

Authority: Sec. 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b).

2. Section 520.812 is amended by redesignating existing paragraph (c) as paragraph (d), by reserving paragraph (c), and by revising newly redesignated paragraph (d) to read as follows:

§ 520.812 Enrofloxacin tablets.

* * * * *

(c) [Reserved]

(d) *Conditions of use.* (1) *Amount.* 5 to 20 milligrams per kilogram (2.27 to 9.07 milligrams per pound) of body weight.

(2) *Indications for use.* Dogs and cats for management of diseases associated with bacteria susceptible to enrofloxacin.